Access to and affordability of CAR T-cell therapy in multiple myeloma: an EBMT position paper
Standard
Access to and affordability of CAR T-cell therapy in multiple myeloma: an EBMT position paper. / Gagelmann, Nico; Sureda, Anna; Montoto, Silvia; Murray, John; Bolaños, Natacha; Kenyon, Michelle; Beksac, Meral; Schönland, Stefan; Hayden, Patrick; Scheurer, Hans; Morgan, Kate; Garderet, Laurent; McLornan, Donal P; Ruggeri, Annalisa.
in: LANCET HAEMATOL, Jahrgang 9, Nr. 10, 10.2022, S. e786-e795.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Review › Forschung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Access to and affordability of CAR T-cell therapy in multiple myeloma: an EBMT position paper
AU - Gagelmann, Nico
AU - Sureda, Anna
AU - Montoto, Silvia
AU - Murray, John
AU - Bolaños, Natacha
AU - Kenyon, Michelle
AU - Beksac, Meral
AU - Schönland, Stefan
AU - Hayden, Patrick
AU - Scheurer, Hans
AU - Morgan, Kate
AU - Garderet, Laurent
AU - McLornan, Donal P
AU - Ruggeri, Annalisa
N1 - Copyright © 2022 Elsevier Ltd. All rights reserved.
PY - 2022/10
Y1 - 2022/10
N2 - Chimeric antigen receptor (CAR) T-cell therapy is a promising immunotherapeutic approach in the treatment of multiple myeloma, and the recent approval of the first two CAR T-cell products could result in improved outcomes. However, it remains a complex and expensive technology, which poses challenges to health-care systems and society in general, especially in times of crises. This potentially accelerates pre-existing inequalities as access to CAR T-cell therapy varies, both between countries, depending on the level of economic development, and within countries, due to structural disparities in access to quality health care-a parameter strongly correlated with socioeconomic status, ethnicity, and lifestyle. Here, we identify two important issues: affordability and access to CAR T-cell treatment. This consensus statement from clinical investigators, clinicians, nurses, and patients from the European Society for Blood and Marrow Transplantation (EBMT) proposes solutions as part of an innovative collaborative strategy to make CAR T-cell therapy accessible to all patients with multiple myeloma.
AB - Chimeric antigen receptor (CAR) T-cell therapy is a promising immunotherapeutic approach in the treatment of multiple myeloma, and the recent approval of the first two CAR T-cell products could result in improved outcomes. However, it remains a complex and expensive technology, which poses challenges to health-care systems and society in general, especially in times of crises. This potentially accelerates pre-existing inequalities as access to CAR T-cell therapy varies, both between countries, depending on the level of economic development, and within countries, due to structural disparities in access to quality health care-a parameter strongly correlated with socioeconomic status, ethnicity, and lifestyle. Here, we identify two important issues: affordability and access to CAR T-cell treatment. This consensus statement from clinical investigators, clinicians, nurses, and patients from the European Society for Blood and Marrow Transplantation (EBMT) proposes solutions as part of an innovative collaborative strategy to make CAR T-cell therapy accessible to all patients with multiple myeloma.
KW - Costs and Cost Analysis
KW - Ethnicity
KW - Humans
KW - Immunotherapy, Adoptive
KW - Multiple Myeloma/therapy
KW - Receptors, Chimeric Antigen
U2 - 10.1016/S2352-3026(22)00226-5
DO - 10.1016/S2352-3026(22)00226-5
M3 - SCORING: Review article
C2 - 36174641
VL - 9
SP - e786-e795
JO - LANCET HAEMATOL
JF - LANCET HAEMATOL
SN - 2352-3026
IS - 10
ER -
